Cryo-Cell International IncCCEL
Price$4.05

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $31.1M-2.7% YoYTTM through 31 May 2026
Net Income -$2.5M-713.4% YoYTTM through 31 May 2026
Free Cash Flow $6.1MTTM through 31 May 2026

Margins

Current
Gross Margin76.7%
EBITDA Margin2.8%
Operating Margin-0.3%
Net Margin-7.9%

Returns

12.9%ROE
-3.9%ROA

Balance Sheet Health

Debt / Equity-0.58x
Current Ratio0.61x
Net Debt$7.5M
Cash & Equivalents$507.3K

Quality Metrics

Altman Z-Score-0.20
Piotroski F-Score5 / 9
FCF Margin19.6%
Earnings-Beat Rate75.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $31.6M
Diluted EPS-$0.31TTM
'19'20'21'22'23'24'25
FY2025: $-0.30

Dividend

$0.40Per share, FY20259.62%Yield1 yrsStreak

Capital Allocation

R&D Spend$312K
Capex Intensity0.7%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.